bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
Investment Announcement: bioAffinity Technologies has entered into securities purchase agreements for the sale of 990 shares of Series B Convertible Preferred Stock and warrants, aiming to raise approximately $1.2 million for working capital and corporate purposes.
CyPath® Lung Test: The company’s noninvasive test, CyPath® Lung, demonstrates high sensitivity and accuracy in detecting early-stage lung cancer, utilizing advanced flow cytometry and AI technology.
Trade with 70% Backtested Accuracy
Analyst Views on BIAFW
No data
About the author
BIOAFFINITY TECHNOLOGIES REPORTS RECORD REVENUE AND UNIT SALES FOR CYPATH® LUNG, ITS LEADING LUNG CANCER DIAGNOSTIC, IN 2025
Record Revenue Announcement: BioAffinity Technologies has announced record revenue for 2025, indicating strong financial performance.
Unit Sales Growth: The company reported significant unit sales for its flagship product, the Lung Cancer Diagnostic CyPath®, highlighting its market success.
bioAffinity Technologies Sees Rapid Month-Over-Month Increase in CyPath® Lung Test Volume
Sales Growth of CyPath® Lung: bioAffinity Technologies reported a 111% increase in test volume for its noninvasive lung cancer diagnostic test, CyPath® Lung, in October 2025 compared to the monthly average for the first nine months of the year, indicating strong adoption by physicians.
Clinical Value Recognition: The increase in test volume reflects growing recognition among clinicians of the test's clinical value in early lung cancer detection, particularly for patients with indeterminate pulmonary nodules.
Consistent Growth Trends: Throughout 2025, CyPath® Lung has shown consistent month-over-month and quarter-over-quarter sales growth, with a 95% increase in third-quarter sales compared to the previous quarter.
Technology and Accuracy: CyPath® Lung utilizes advanced flow cytometry and AI for detecting malignancy in sputum samples, achieving 92% sensitivity and 88% accuracy in clinical studies, which underscores its potential to improve early-stage lung cancer diagnosis and patient outcomes.
bioAffinity Technologies, Inc. Completes $1.8 Million Registered Direct Offering of Common Stock at Market Price in Accordance with Nasdaq Regulations
Stock Offering Announcement: bioAffinity Technologies, Inc. has completed a registered direct offering of 720,000 shares of common stock at $2.50 per share, with proceeds intended for working capital and to support sales growth of its noninvasive lung cancer test, CyPath® Lung.
Company Overview: bioAffinity Technologies focuses on noninvasive cancer diagnostics, with its primary product, CyPath® Lung, demonstrating high sensitivity and accuracy for early-stage lung cancer detection, marketed through its subsidiary, Precision Pathology Laboratory Services.
bioAffinity Technologies, Inc. Reveals About $1.8 Million Registered Direct Offering of Common Stock Priced According to Nasdaq Regulations
Stock Offering Announcement: bioAffinity Technologies, Inc. has announced a registered direct offering of 720,000 shares of common stock at $2.50 per share, expected to close around October 9, 2025, with gross proceeds estimated at $1.8 million.
Use of Proceeds: The company plans to use the net proceeds for working capital, supporting sales growth of its noninvasive lung cancer test, CyPath® Lung, and for general corporate purposes.
bioAffinity Technologies Completes $4.8 Million Public Offering
Public Offering Announcement: bioAffinity Technologies, Inc. has successfully closed a public offering of securities, raising $4.8 million through the sale of 1,921,761 shares of Common Stock at a price of $2.50 per share.
Product Focus: The company specializes in noninvasive tests for early-stage cancer detection, with its first product, CyPath® Lung, demonstrating high sensitivity and accuracy for detecting early-stage lung cancer.
bioAffinity Technologies Expands Collection of Case Studies Highlighting Clinical Benefits of CyPath® Lung
Noninvasive Lung Cancer Detection: bioAffinity Technologies has released case studies demonstrating that its noninvasive diagnostic test, CyPath® Lung, successfully detected Stage 1A lung cancer and helped avoid unnecessary invasive procedures for patients with indeterminate lung nodules.
Clinical Impact and Technology: The test utilizes advanced flow cytometry and AI to analyze sputum samples, achieving high sensitivity and specificity in identifying lung cancer, thereby enhancing clinical decision-making and potentially improving patient outcomes.
BIOAFFINITY TECHNOLOGIES REPORTS RECORD REVENUE AND UNIT SALES FOR CYPATH® LUNG, ITS LEADING LUNG CANCER DIAGNOSTIC, IN 2025
Record Revenue Announcement: BioAffinity Technologies has announced record revenue for 2025, indicating strong financial performance.
Unit Sales Growth: The company reported significant unit sales for its flagship product, the Lung Cancer Diagnostic CyPath®, highlighting its market success.
bioAffinity Technologies Sees Rapid Month-Over-Month Increase in CyPath® Lung Test Volume
Sales Growth of CyPath® Lung: bioAffinity Technologies reported a 111% increase in test volume for its noninvasive lung cancer diagnostic test, CyPath® Lung, in October 2025 compared to the monthly average for the first nine months of the year, indicating strong adoption by physicians.
Clinical Value Recognition: The increase in test volume reflects growing recognition among clinicians of the test's clinical value in early lung cancer detection, particularly for patients with indeterminate pulmonary nodules.
Consistent Growth Trends: Throughout 2025, CyPath® Lung has shown consistent month-over-month and quarter-over-quarter sales growth, with a 95% increase in third-quarter sales compared to the previous quarter.
Technology and Accuracy: CyPath® Lung utilizes advanced flow cytometry and AI for detecting malignancy in sputum samples, achieving 92% sensitivity and 88% accuracy in clinical studies, which underscores its potential to improve early-stage lung cancer diagnosis and patient outcomes.
bioAffinity Technologies, Inc. Completes $1.8 Million Registered Direct Offering of Common Stock at Market Price in Accordance with Nasdaq Regulations
Stock Offering Announcement: bioAffinity Technologies, Inc. has completed a registered direct offering of 720,000 shares of common stock at $2.50 per share, with proceeds intended for working capital and to support sales growth of its noninvasive lung cancer test, CyPath® Lung.
Company Overview: bioAffinity Technologies focuses on noninvasive cancer diagnostics, with its primary product, CyPath® Lung, demonstrating high sensitivity and accuracy for early-stage lung cancer detection, marketed through its subsidiary, Precision Pathology Laboratory Services.
bioAffinity Technologies, Inc. Reveals About $1.8 Million Registered Direct Offering of Common Stock Priced According to Nasdaq Regulations
Stock Offering Announcement: bioAffinity Technologies, Inc. has announced a registered direct offering of 720,000 shares of common stock at $2.50 per share, expected to close around October 9, 2025, with gross proceeds estimated at $1.8 million.
Use of Proceeds: The company plans to use the net proceeds for working capital, supporting sales growth of its noninvasive lung cancer test, CyPath® Lung, and for general corporate purposes.
bioAffinity Technologies Completes $4.8 Million Public Offering
Public Offering Announcement: bioAffinity Technologies, Inc. has successfully closed a public offering of securities, raising $4.8 million through the sale of 1,921,761 shares of Common Stock at a price of $2.50 per share.
Product Focus: The company specializes in noninvasive tests for early-stage cancer detection, with its first product, CyPath® Lung, demonstrating high sensitivity and accuracy for detecting early-stage lung cancer.
bioAffinity Technologies Expands Collection of Case Studies Highlighting Clinical Benefits of CyPath® Lung
Noninvasive Lung Cancer Detection: bioAffinity Technologies has released case studies demonstrating that its noninvasive diagnostic test, CyPath® Lung, successfully detected Stage 1A lung cancer and helped avoid unnecessary invasive procedures for patients with indeterminate lung nodules.
Clinical Impact and Technology: The test utilizes advanced flow cytometry and AI to analyze sputum samples, achieving high sensitivity and specificity in identifying lung cancer, thereby enhancing clinical decision-making and potentially improving patient outcomes.
